Resistant Hypertension in Chronic Kidney Disease

358

Color Doppler sonography, 18, 19
Compliance, 189–191
Confidence interval (CI), 80
Continuous ambulatory peritoneal dialysis
(CAPD), 310
Continuous positive airway pressure (CPAP),
324–328
in HT, 328
mechanisms of action, 328
nocturnal blood pressure reduction, 209
role, 327
therapy
vs. antihypertensives, blood pressure
control, 209, 210
blood pressure, 206–208
resistant hypertension, 208, 209
Controlled resistant hypertension
(cRH), 66
Cox proportional hazard regression, 64
Cushing’s syndrome, 46
Cyclic adenosine 3′,5′-monophosphate
(cAMP), 106
Cyclooxygenase-2 inhibitors, 84
Cyclosporine, 46

D
Darusentan, 224
Device-Based Therapy in Hypertension Trial
(DEBuT-HT), 157–158
Devices, nural modulation, 310–314
DEW-IT study, 240
Diabetes mellitus (DM), 30, 85
Diabetic nephropathy, 13, 14, 16, 17
Dialysis Outcomes and Practice Patterns Study
(DOPPS), 297
Diastolic blood pressure (DBP), 15, 186
Dietary Approaches to Stop Hypertension
(DASH), 237, 239, 240, 248
Dietary sodium intake, 220
Diuretic drug, 35
Diuretics, 291, 300
D1-like and D2-like receptors, 106
Dopamine, 104–106
Duplex sonography, 34
Dyslipidemia, 85

E
Echocardiography, 267
Efferent renal sympathetic nerve activity
(ERSNA), 94
Eighth Joint National Committee (JNC 8),
186, 233

Eight-item Morisky Medication Adherence

Scale (MMAS-8), 238

Elderly

blood pressure targets, 185, 186

CKD, 184, 185

guidelines, 186

population, 184 (see also Resistant

hypertension (RH))

Endocapillary (acute) GN, 17

Endocrinological diseases, 84

Endothelial glycocalyx layer (EGL), 171

Endothelial luminal surface (EnNaC), 172

Endothelial surface layer, 172

Endothelins, 133, 224

antagonists, 299–300

system, 225

Endothelium-derived relaxing factors

(EDRFs), 161

Endovascular renal nerve ablation, 311

End-stage renal disease (ESRD), 41, 79, 132,

162, 172, 324

Epithelial Na+ channel (ENaC), 106

Epworth Sleepiness Scale (ESS), 204

Erythropoiesis-stimulating agents

(ESA), 135

Erythropoietin, 21

ESH/ESC guidelines, 81, 294

Estimated glomerular filtration rate (eGFR),

15, 139

European Body Composition study, 177

European Society of Cardiology (ESC), 14,

141, 285

European Society of Cardiology and European

Society of Hypertension, 4

European Society of Hypertension (ESH), 14,

141, 323

Extracellular volume (ECV), 48, 176

F

Fatal CV events, 43, 50

FGF23 coreceptor klotho, 31

Fibromuscular dysplasia, 18

Flow-mediated dilatation (FMD), 141

Fourth-line therapy, 222

French Society of Arterial Hypertension, 285

G

Gas chromatography–mass spectrometry

(GC–MS), 238

General practitioners (GPs), 243, 343

Genetics of Hypertension Associated

Treatment Study, 113

Index